Results 11 to 20 of about 4,259,087 (330)

Thirty years of HDAC inhibitors: 2020 hindsight. [PDF]

open access: yesJournal of Medicinal Chemistry, 2020
It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical ...
Terence C. S. Ho, A. Chan, Arasu Ganesan
semanticscholar   +2 more sources

HDACs and HDAC Inhibitors in Cancer Development and Therapy [PDF]

open access: yesCold Spring Harbor Perspectives in Medicine, 2016
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Post-translational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating
Yixuan Li, E. Seto
semanticscholar   +3 more sources

DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro [PDF]

open access: yesFrontiers in Genetics, 2022
Cutaneous T-cell lymphomas (CTCLs) are a subset of T-cell malignancies presenting in the skin. The treatment options for CTCL, in particular in advanced stages, are limited.
Eliza Mari Kwesi-Maliepaard   +8 more
doaj   +2 more sources

Current HDAC Inhibitors in Clinical Trials.

open access: yesCHIMIA, 2022
Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression.
Elisabetta Di Bello   +3 more
semanticscholar   +5 more sources

HDAC Inhibitors in Acute Myeloid Leukemia [PDF]

open access: yesCancers, 2019
Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled proliferation, differentiation arrest, and accumulation of immature myeloid progenitors.
Edurne San José-Enériz   +3 more
semanticscholar   +4 more sources

HDAC inhibitors in parasitic diseases

open access: yesImmunology & Cell Biology, 2011
Parasitic diseases cause significant global morbidity and mortality, particularly in underdeveloped regions of the world. Malaria alone causes ∼800 000 deaths each year, with children and pregnant women being at highest risk. There is no licensed vaccine available for any human parasitic disease and drug resistance is compromising the efficacy of many ...
Andrews, Katherine T.   +2 more
openaire   +6 more sources

Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir [PDF]

open access: yesmBio
The HIV reservoir is more dynamic than previously thought with around 70% of the latent reservoir originating from viruses circulating within 1 year of the initiation of antiretroviral therapy (ART).
Lijun Ling   +13 more
doaj   +2 more sources

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

open access: yesBritish Journal of Clinical Pharmacology, 2021
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials ...
A. D. Bondarev   +5 more
semanticscholar   +1 more source

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

open access: yesPharmaceutics, 2022
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors.
Dusan Ruzic   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy